Acadia Pharma (ACAD) reported Q2 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $134.6 million versus the consensus estimate...
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Oil & Gas, Consumer Goods and Telecoms sectors led shares higher. At the close in NYSE, the Dow...
The S&P 500 fell by around 1%. The FOMC minutes came as I expected, indicating $95 billion a month in roll-off of the balance sheet, to start with. I had been looking for $100...
1. S&P 500It will be a critical week for stocks after two weeks of gains. The S&P 500 finished Friday in an exciting spot and at more than one inflection point. It could...
ACADIA Pharmaceuticals (NASDAQ:ACAD) Inc. ACAD announced that it intends to resubmit the supplemental new drug application (sNDA) for its marketed drug, Nuplazid (pimavanserin),...
Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The Company has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The Company also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).
|Average||23.38 (+39.55% Upside)|
|No. of Analysts||16|